Share
The Endocrine Society responded to the Centers for Medicare and Medicaid Services (CMS) proposed Medicare Physician Fee Schedule (MPFS) by advocating to maintain increase for endocrinology. This annual rule updates payment policies and payment rates for Part B services furnished under the MPFS. Every year, CMS requests public comment on its proposed changes. We are pleased that the proposed...
Share
While Congress avoided the U.S. defaulting on its loans and an international financial disaster by reaching a deal to suspend the country’s the debt limit, the deal included budget caps that will dramatically affect federal spending for the next two years. This agreement on budget caps now extends to congressional decisions on the annual appropriations...
Share
In June, legislation to reauthorize the Special Diabetes Program (SDP) advanced in Congress and the Endocrine Society played a leading role in advocating for the legislation. Introduced in both the House and Senate, this legislation would reauthorize both components of the program through December 2025. The House Energy and Commerce Committee unanimously approved a House...
Share
The American Medical Association (AMA) House of Delegates unanimously passed a resolution sponsored by the Endocrine Society to protect access to evidence-based gender-affirming care for transgender and gender-diverse individuals. The Endocrine Society partnered with the American Association of Clinical Endocrinology (AACE), the American Society for Reproductive Medicine (ASRM), and the Medical Student Section of the...
Share
On April 17, a group of Endocrine Society members walked the halls of Congress to meet with their elected representatives and advocate for our priorities related to funding for biomedical research and treatment and prevention of diabetes. Our asks were timely and important; we urged Congress to support an overall funding level of $51 billion...
Share
Last month, three of the largest insulin manufacturers announced they would take steps to reduce the price of their insulins. Eli Lilly and Company first announced it would reduce the list price for certain insulins by 70% and extend the $35 per month cap on out-of-pocket costs for people with Medicare that was enacted in...
Share
We are only a few months into 2023, but the Endocrine Society has been busy advocating for its members. The Endocrine Society has traveled near (to Capitol Hill) and far (to Brussels and Bangkok) to advocate for our policy priorities. Our priorities include improved research, treatment, and prevention of diabetes; awareness of endocrine-related research, opportunities,...
Share
The Endocrine Society advocates on behalf of our members, the patients they treat, and the science they research. This year, in addition to continuing our virtual advocacy, we had the opportunity to reintroduce several in-person advocacy activities. With help from our members, we successfully advocated for our policy priorities and raised awareness of the value...
